Small rises in blood glucose trigger big changes in insulin-producing cells

April 21, 2020

BOSTON - (April 21, 2020) - In diabetes, tiny clusters of insulin-producing "beta cells" in the pancreas don't produce enough of the hormone to keep people healthy, and their blood glucose levels climb. Perhaps unsurprisingly, their beta cells then function very differently than the cells do in people with normal blood glucose levels.

What's surprising is that the changes in beta-cell behavior begin to occur when the blood glucose levels are barely elevated, still within the pre-diabetes range. "These slightly high concentrations of glucose are enough to really confuse the cell," says Gordon Weir, MD, senior investigator and senior staff physician at Joslin Diabetes Center.

In a paper recently published in Molecular Metabolism, Weir's lab laid out a wealth of new data about how beta cells behave at slightly raised levels of blood glucose. The work provides major additional evidence of a "glucose toxicity" effect that helps to drive the development of both type 1 and type 2 diabetes.

Studying beta cells in lab rats whose blood glucose levels were slightly elevated, Weir's lab found changes in gene expression that affect not just how well the cells function but their ability to divide and grow, as well as their vulnerability to autoimmunity and inflammation.

Weir, professor of medicine at Harvard Medical School, has long studied a puzzling type 2 diabetes phenomenon called first-phase insulin release and how this release is shut down as the disease progresses.

In healthy people with normal blood glucose levels, Weir explains, the body responds quickly to glucose with a big spike of insulin secretion. "If then you take people who have slightly higher glucose levels, above 100 mg/dl, which is still not even diabetes, this first-phase insulin release is impaired," he says. "And when the level gets above 115 mg/dl, it's gone. So virtually all the beta cells don't respond to that acute stimulus." Fortunately, the cells eventually do wake up and respond to other stimuli well enough to keep blood glucose in a prediabetic range.

In earlier research, Weir and collaborators studied this phenomenon in rats who were surgically altered to generate slightly high blood glucose levels, and found that the rats' beta cells secreted less insulin. In their latest experiments, the Joslin team employed the same approach along with powerful "RNA sequencing" methods that revealed patterns of gene expression in the beta cells, either four weeks or ten weeks after surgery. "We found incredible changes in gene expression, and the higher the glucose, the worse the changes," Weir says.

As expected, genes involved in insulin secretion were highly active in the beta cells. More striking were newly discovered alterations in gene expression that could make the cells more vulnerable. Some of these changes were related to cell growth--healthy beta cells may respond to increased blood glucose levels by copying themselves, but these cells were getting stuck as they tried to divide. Additionally, the cells showed many differences in the expression of genes involved in cell inflammation and autoimmunity.

In type 1 diabetes, immune cells called "T cells" begin to kill off the beta cells and blood glucose levels start to creep up. Weir's team found that in the rats with just slightly greater glucose levels, beta cells showed dramatic increases in the expression of some key genes involved in T cell interactions. That effect could make the beta cells a better target for autoimmune attack, and thus speed the disease.

This finding may improve the understanding of the rapid death of beta cells that patients typically experience just before they are diagnosed with type 1 diabetes, Weir says. It also might shed light on the "honeymoon" period some people experience after diagnosis, in which their blood glucose levels are relatively easy to control. During this period, if insulin treatments can bring the remaining beta cells back down to only slightly elevated glucose levels, the cells can function much better, he says.

Glucose toxicity also might trigger the loss of first-phase insulin release as type 2 diabetes develops, Weir says. Immunologists often blamed this loss on inflammation of the beta cells, but other studies have shown that less than half of these cells appear to suffer from inflammation. "So somehow these beta cells with no evidence of inflammation end up not secreting properly," Weir says. "We think these higher glucose levels are causing the trouble."

More evidence for the role of higher blood glucose levels in type 2 diabetes comes from the subset of people undergoing gastric bypass surgery who are "cured" of diabetes and return to healthy blood glucose levels. "Their first-phase insulin release also comes right back to normal, which fits perfectly with our hypothesis," he says.
-end-
Aref Ebrahimi, a Harvard student working in the Weir lab, was lead author on the paper. Joslin's Jennifer Hollister-Lock, Brooke Sullivan, Ryohei Tsuchida and Susan Bonner-Weir were co-authors. Lead support came from the National Institutes of Health, the Research and Wellness Foundation and Joslin's Diabetes Research Center.

About Joslin Diabetes Center

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives.  We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 16 NIH-designated Diabetes Research Centers in the U.S.

For more information, visit http://www.joslin.org or follow @joslindiabetes | One Joslin Place, Boston, MA 617-309-2400

Joslin Diabetes Center

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.